ZYME Form 4: Director's 415k Share Purchase and 62,000 Option Grant

Rhea-AI Filing Summary

Gregory Austin Ciongoli, a director of Zymeworks Inc. (ZYME), reported acquisitions of company securities in August 2025. The Form 4 shows he acquired 415,000 shares of common stock on 08/12/2025 at a price of $12.02, bringing his reported direct beneficial ownership to 488,500 shares.

The filing also discloses an indirect holding of 5,000 shares held by 4 Arrows Holdings, LLC, for which he is manager, and a grant of 62,000 stock options on 08/11/2025 with an exercise price of $12.44. The options vest in 36 equal monthly installments beginning one month after the grant date and show an expiration date of 08/10/2035. The Form 4 was signed by an attorney-in-fact on 08/12/2025.

Positive

• Director acquired 415,000 shares on 08/12/2025 at $12.02, increasing direct beneficial ownership to 488,500 shares
• Granted 62,000 stock options on 08/11/2025 with a $12.44 exercise price and explicit 36-month monthly vesting
• Disclosed indirect holdings of 5,000 shares via 4 Arrows Holdings, LLC, with clear statement of managerial voting/dispositive power

Negative

• None.

Insights

Financial Analyst

Insider purchased a substantial block and received time‑vesting options, increasing reported insider holdings.

The Form 4 records a 415,000-share purchase at $12.02 and a simultaneous disclosure of 488,500 shares held directly after the transaction. It also documents a 62,000-option grant with a $12.44 strike that vests monthly over 36 months, which ties compensation to multi‑year service. For investors, the itemized quantities and prices are clear and verifiable in the filing; the transactions are material as disclosure items but do not on their face reveal company performance metrics.

Corporate Governance Expert

Grant structure and indirect holdings are clearly disclosed; vesting schedule indicates retention-oriented award.

The filing specifies that 5,000 shares are held by 4 Arrows Holdings, LLC, for which the reporting person is manager and over which he claims sole voting and dispositive power while disclaiming beneficial ownership except for pecuniary interest. The option grant's 36-month monthly vesting beginning one month after the August 11, 2025 grant aligns incentives over time. The Form 4 is properly executed by an attorney-in-fact on 08/12/2025, and disclosures include exercise price, grant date, and expiration date, supporting transparency in governance reporting.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ciongoli Gregory Austin

(Last) (First) (Middle)

C/O ZYMEWORKS INC.

108 PATRIOT DRIVE, SUITE A

(Street)

MIDDLETOWN DE 19709

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Zymeworks Inc. [ ZYME ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/12/2025		A		415,000	A	$12.02	488,500	D
Common Stock								5,000	I	See footnote(1)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$12.44	08/11/2025		A		62,000		(2)	08/10/2035	Common Stock	62,000	$0.00	62,000	D

Explanation of Responses:

1. Represents shares held by 4 Arrows Holdings, LLC, for which the reporting person is the manager. The reporting person exercises sole voting and dispositive power over these shares and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

2. Stock options vest in 36 equal monthly installments starting one month after grant date of August 11, 2025.

	/s/ Daniel Dex, Attorney-in-Fact	08/12/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did ZYME director Gregory Ciongoli report on the Form 4?

The Form 4 reports a purchase of 415,000 common shares on 08/12/2025 at $12.02 and a grant of 62,000 stock options on 08/11/2025 with a $12.44 exercise price.

How many shares does Gregory Ciongoli beneficially own after the reported transactions?

The filing shows 488,500 shares beneficially owned directly following the reported transactions and an indirect holding of 5,000 shares held by 4 Arrows Holdings, LLC.

What are the terms and vesting schedule of the option grant reported on Form 4?

The Form 4 lists 62,000 options with a $12.44 exercise price, vesting in 36 equal monthly installments starting one month after the grant date of 08/11/2025, and an expiration date shown as 08/10/2035.

What is the nature of the indirect ownership reported in the filing?

Footnote (1) states the 5,000 shares are held by 4 Arrows Holdings, LLC, for which the reporting person is the manager and exercises sole voting and dispositive power while disclaiming beneficial ownership except for pecuniary interest.

When was the Form 4 signed and filed?

The Form 4 bear a signature by an attorney-in-fact, /s/ Daniel Dex, dated 08/12/2025.